Laparoscopic-Assisted Natural Orifice Surgery for Colonic Resection Procedures

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Colonic Resection Procedures
Laparoscopic-Assisted Natural Orifice Surgery - Procedure
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new, minimally invasive technique for colon surgery in women, which may lead to fewer infections and a shorter hospital stay.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Post-operative day 1 through 1 year

Year 1
Incidence of Post-operative Infections
Post-operative Pain

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Traditional Laparoscopic-Assisted Colectomy
1 of 2
Transvaginal Laparoscopic-Assisted Colectomy
1 of 2
Active Control
Experimental Treatment

110 Total Participants · 2 Treatment Groups

Primary Treatment: Laparoscopic-Assisted Natural Orifice Surgery · No Placebo Group · N/A

Transvaginal Laparoscopic-Assisted Colectomy
Procedure
Experimental Group · 1 Intervention: Laparoscopic-Assisted Natural Orifice Surgery · Intervention Types: Procedure
Traditional Laparoscopic-Assisted ColectomyNoIntervention Group · 1 Intervention: Traditional Laparoscopic-Assisted Colectomy · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: post-operative day 1 through 1 year

Who is running the clinical trial?

Jaime SanchezLead Sponsor
Jaime Sanchez, MDPrincipal InvestigatorUniversity of South Florida

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 11th, 2021

Last Reviewed: October 6th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.